Listenly

How should procurement teams build relationships with internal R&D teams in pharma companies?

Answered at 20:09 in Drug Development Is a Team Sport — And Procurement Has to Play. · Executive Edge Podcast

— questions searchable right now

How should procurement teams build relationships with internal R&D teams in pharma companies?

Procurement must actively seek out R&D staff through coffee meetings and lunches to listen and understand their needs rather than waiting for them to approach. Instead of acting as a budget master or imposing bureaucratic constraints, procurement should find common vocabulary around regulatory and scientific aspects, help them maximize value from budgets, and continuously cultivate trusted relationships while flexing on parameters as projects evolve.

Dave Stowe on Executive Edge PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

Procurement must actively seek out R&D staff through coffee meetings and lunches to listen and understand their needs rather than waiting for them to approach.

Dave Stowe, Founder and Managing Partner at Adventus · Drug Development Is a Team Sport — And Procurement Has to Play. · Executive Edge Podcast · answer at 20:09

Key takeaways

  • Procurement must actively seek out R&D staff through coffee meetings and lunches to listen and understand their needs rather than waiting for them to approach.

Quote to remember

“Somehow you've got to build those relationships. And I feel like when I've seen bad situations happen is people in the pharma space and the finance procurement do not extend it. They say, well, they should come and find me. And I'd say, no, it's the other way around. We need to go to them.”

— Dave Stowe

The full answer · about 2 min

Procurement must actively seek out R&D staff through coffee meetings and lunches to listen and understand their needs rather than waiting for them to approach. Instead of acting as a budget master or imposing bureaucratic constraints, procurement should find common vocabulary around regulatory and scientific aspects, help them maximize value from budgets, and continuously cultivate trusted relationships while flexing on parameters as projects evolve.

Key facts

  • Three main phases of clinical trials: Phase One, Two, and Three
  • Biotech spending scale progression: $20 million to $40 million to $80 million to $100 million to $200 million annually in drug development
  • Viagra development timeline: designed for heart treatment over 20 years ago before pivoting to different therapeutic use
  • Preclinical stage triggers: investigational new drug (IND) setup marks transition requiring more investor money and structured relationships
  • Patent protection: limited time period for pharmaceutical companies to recoup investments before drugs lose patent exclusivity and become subject to generic competition

People, companies and topics mentioned

AdventusContract Research Organizations (CROs)PwCOliver WymanHorizon TherapeuticsPurdue PharmaFDAInvestigational New Drug (IND)

More answers from this episode

 ·  All answers from Executive Edge Podcast →
—
—
0:00
0:00